Get the Stockscreener App
34.45
0.01%
-0.0024
Exelixis Inc stock is traded at $34.45, with a volume of 854.53K.
It is down -0.01% in the last 24 hours and up +19.19% over the past month.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$34.45
Open:
$34.15
24h Volume:
854.53K
Relative Volume:
0.42
Market Cap:
$9.81B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
121.59
EPS:
0.2833
Net Cash Flow:
$404.94M
1W Performance:
-4.82%
1M Performance:
+19.19%
6M Performance:
+64.73%
1Y Performance:
+63.01%
1-Day Range:
$34.06
$34.57
1-Week Range:
$34.06
$36.49
52-Week Range:
$19.20
$36.60
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| EXEL | 34.45 | 9.81B | 2.08B | 466.92M | 404.94M | 0.2833 |
| VRTX | 467.02 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 759.96 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 231.19 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.53 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Janney Montgomery Scott LLC Cuts Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Seizert Capital Partners LLC - MarketBeat
1 No-Brainer Stock to Buy With $40 - AOL
Cornercap Investment Counsel Inc. Reduces Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Entropy Technologies LP Invests $475,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Receives $31.44 Consensus Target Price from Analysts - MarketBeat
Principal Financial Group Inc. Reduces Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - MSN
CWA Asset Management Group LLC Invests $577,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Here's Why Exelixis (EXEL) is a Strong Value Stock - MSN
What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now? - MSN
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now - MSN
Los Angeles Capital Management LLC Has $46.47 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Van ECK Associates Corp Boosts Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Have Insiders Sold Exelixis Shares Recently? - Simply Wall St
Exelixis CSO Aftab Dana sells $3.39 million in stock - Investing.com
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - BioSpace
Exelixis CSO Aftab Dana sells $3.39 million in stock By Investing.com - Investing.com UK
Exelixis to shed 212K sf of industrial in Alameda - The Real Deal
Robeco Institutional Asset Management B.V. Purchases 350,026 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis stock soars to 52-week high, reaches $35.76 - Investing.com
Exelixis's SWOT analysis: oncology leader's stock poised for growth By Investing.com - Investing.com Australia
Exelixis EVP sells $1.7 million in stock - Investing.com India
Exelixis EVP sells $1.7 million in stock By Investing.com - Investing.com Canada
Exelixis director George Poste sells $1.02 million in shares - Investing.com India
Exelixis director George Poste sells $1.02 million in shares By Investing.com - Investing.com Canada
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain? - MSN
Exelixis (NASDAQ:EXEL) Sets New 52-Week HighTime to Buy? - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Capital Management Corp VA - MarketBeat
Exelixis's SWOT analysis: oncology leader's stock poised for growth - Investing.com India
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook - MSN
Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool
New York State Teachers Retirement System Purchases 20,008 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Dana Aftab Sells 1,162 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock - MarketBeat
Exelixis cso sells stock worth $36,486 By Investing.com - Investing.com Australia
Exelixis cso sells stock worth $36,486 - Investing.com India
Exelixis (NASDAQ:EXEL) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Trend Tracker for (EXEL) - Stock Traders Daily
Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Exelixis price target raised to $38 from $33 at Truist - MSN
Stephens Investment Management Group LLC Has $98.78 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Call Transcript - Insider Monkey
Exelixis stock hits 52-week high at $31.3 amid robust growth - Investing.com Australia
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance - Investing.com
Earnings call: Exelixis reports solid growth, raises 2024 revenue guidance By Investing.com - Investing.com UK
Exelixis price target raised to $36 from $33 at Piper Sandler - Yahoo Finance
DekaBank Deutsche Girozentrale Acquires 30,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exelixis Inc Stock (EXEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Aftab Dana | CSO/EVP Disc & Trans Research |
Nov 05 '24 |
Sale |
35.00 |
96,986 |
3,394,510 |
498,945 |
| Hessekiel Jeffrey | EVP & General Counsel |
Nov 01 '24 |
Sale |
34.13 |
50,000 |
1,706,500 |
530,325 |
| POSTE GEORGE | Director |
Nov 01 '24 |
Sale |
34.00 |
30,000 |
1,020,000 |
169,020 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):